Last checked at 18 May 2023 07:00
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum announces the commencement of a Phase 1a clinical trial for SDC-1801
Cambridge, UK, 18 May 2023 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the initiation of a Phase 1a clinical trial for its lead product SDC-1801. The trial has started with patient recruitment in progress at specialist clinical units located in Victoria, Australia.
SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
This follows the recent approval of the Company's application under the Clinical Trial Notification (CTN) scheme by the Human Research Ethics Committee (HREC). Australia's medicines regulator, the Therapeutic Goods Administration (TGA), has also acknowledged the application, allowing for the Phase 1a trial to proceed.
The initial Phase 1a trial is designed to investigate the safety and pharmacokinetics of an oral formulation of SDC-1801 in healthy subjects (trial ID ACTRN12623000416695p). Provided satisfactory safety data are obtained from this initial study, a Phase 1b clinical study is expected to commence in psoriasis patients in 2024.
-Ends-
For further information, please contact:
Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations |
01223 497700 ir@sareum.co.uk
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth
|
020 7418 8900 |
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3709 5700 |
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com